MIL97 / Beijing Mabworks Biotech - LARVOL DELTA

Fc-Optimized Agonistic Anti-Human CD40 mAb Demonstrates Strong Antitumor Activity in hCD40/hFcγRIIB Dual Humanized Mice (IMMUNOLOGY 2024) - "Meanwhile, we observed the toxicity indicated by the body weight change and liver function damage of the MIL97-hFc in hCD40/hFcγRIIB mice, mirror clinical toxicities. Collectively, the hCD40/hFcγRIIB mice provide a powerful preclinical model to predict the activity and safety of anti-hCD40 antibodies in vivo, especially of human-specific Fc-engineered antibodies."

IO biomarker • Late-breaking abstract • Preclinical • Oncology • CD40

Treatment of Advanced and Metastatic Solid Tumors With MIL97 (clinicaltrials.gov) - P1 | N=62 | Recruiting | Sponsor: Beijing Mabworks Biotech Co., Ltd. | Trial completion date: Jan 2024 ➔ Dec 2026 | Trial primary completion date: Dec 2023 ➔ Dec 2025

Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

LTC004-01: Clinical Trial for Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - P2 | N=26 | Not yet recruiting | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Combination therapy • Metastases • New P2 trial • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor